WO2000038704A1 - Utilisation d'un peptide - Google Patents
Utilisation d'un peptide Download PDFInfo
- Publication number
- WO2000038704A1 WO2000038704A1 PCT/JP1999/007199 JP9907199W WO0038704A1 WO 2000038704 A1 WO2000038704 A1 WO 2000038704A1 JP 9907199 W JP9907199 W JP 9907199W WO 0038704 A1 WO0038704 A1 WO 0038704A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- seq
- acid sequence
- polypeptide
- protein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2257—Prolactin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Definitions
- the present invention relates to the use of a bioactive peptide. More specifically, the present invention relates to an oxytocin secretion regulator containing a ligand-polypeptide for a G protein-coupled receptor (sometimes called a receptor) protein and the like.
- a bioactive peptide More specifically, the present invention relates to an oxytocin secretion regulator containing a ligand-polypeptide for a G protein-coupled receptor (sometimes called a receptor) protein and the like.
- G protein conjugated guanine nucleotide binding protein
- TMR seven-transmembrane receptor
- G protein-coupled receptor protein is the human receptor encoded by the phGR3 (or sometimes GPR10) gene. Yuichi protein [Genomics, Vol. 29, p. 335 (1995)] and the corresponding rat-type receptor Yuichi protein UHR-1 [Biochemical and Biophysical Research-Communication (Biochem. Biophy. Res. ), Vol. 2009, pp. 606 (1995)].
- Pr RP (Nature, Vol. 393, 2772 — 276 (1998)] is a physiologically active peptide that functions as a ligand for the above-mentioned phGR3 and UHR-1. It has been known.
- P r RP has a specific prolactin-releasing effect on anterior pituitary hormone in an in vitro pituitary cell culture system [Nature, Vol. 393, 272–2]. Pp. 76 (1 998)] but other physiological effects, especially after the pituitary The effects on leaf hormones are not clear.
- the endogenous regulatory hormone that regulates the posterior pituitary hormone oxytocin is currently unknown. Disclosure of the invention
- the present inventors have conducted intensive studies in order to solve the above-mentioned problems.
- two types of specific monoclonal antibodies against P r RP having different recognition sites were prepared, and a highly sensitive P r RP measurement system ( S and wich—EIA type) (Japanese Patent Application No. Hei 10-140293, W99Z60112).
- S and wich—EIA type Japanese Patent Application No. Hei 10-140293, W99Z60112
- PrRP had some effect on the secretion of posterior pituitary hormone.
- intracerebroventricular administration of Pr RP to rats increased the concentration of oxytocin in the blood, and found that P r RP had an effect of regulating oxitosine release.
- an oxytocin secretion regulator containing a ligand peptide or a salt thereof for a G protein-coupled receptor protein
- a ligand peptide or a salt thereof for the G protein-coupled receptor protein comprising a polypeptide having the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 45, or an amide, ester or The oxytocin secretion regulator according to (1), which is a salt thereof;
- oxytocin secretion regulator according to (4), wherein the amino acid sequence represented by SEQ ID NO: 45 is SEQ ID NO: 6, 21, or 35; (6) the oxytocin secretion regulator according to the above (1), which is an oxytocin secretion promoter;
- FIG. 1 shows the rat tissue content of PrRP (19P2-L31).
- FIG. 2 shows the change in blood oxytocin concentration when PrRP (19P2-L31) was administered intracerebroventricularly to 10 nmo1 rats.
- H is or H histidine
- T rt Trityl refers to the activity of a polypeptide (eg, binding activity between a ligand and a receptor) or the activity of a polypeptide to regulate oxytocin secretion. (Eg, oxytocin secretion promoting action, oxytocin secretion inhibiting action, etc.) and the like are substantially the same. Therefore, an “substantially identical” amino acid sequence is defined as the activity of a polypeptide, such as the binding activity between a ligand and a receptor (eg, the binding activity between a ligand and a receptor) or the oxytocin secretion regulating activity of a polypeptide. Amino acid sequence that may have a mutation as long as it remains substantially the same (without significant change) for use (eg, oxytocin secretion promoting action, oxytocin secretion inhibitory action, etc.) Means
- substitutions such as amino acid substitutions, deletions or insertions (additions) in a polypeptide sequence often do not result in significant (significant) changes in the physiological or chemical properties of the polypeptide.
- substitution include the substitution of a certain amino acid for another amino acid having similar properties (characteristics).
- substitution is performed between amino acids having strong similarity in properties. It is considered that the change in the properties of the substitution on the original polypeptide before substitution is small.
- Amino acids are classified into the following classes, for example, based on the similarity of their properties.
- Examples of nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, noline, proline, phenylalanine, tryptophan, and methionine.
- Polar (neutral) amino acids include glycine, serine, threonine, cystine, tyrosine, asparagine and glutamine.
- Positively charged (basic) amino acids include arginine, lysine, histidine and the like.
- Examples of negatively charged (acidic) amino acids include aspartic acid and glutamic acid.
- substantially identical substitution of an amino acid in the amino acid sequence of interest in the present specification for example, it is often selected from other amino acids having similar characteristics among the classes to which the amino acid belongs .
- mutations in the amino acid sequence such as substitutions, deletions, and insertions that do not cause a significant (significant) change in the physiological or chemical properties of the original (unmutated) polypeptide
- the resulting polypeptide (mutated polypeptide) is substantially identical to the original (unmutated) polypeptide without such mutations.
- the amino acid sequence of the variant polypeptide is considered to be substantially identical to the amino acid sequence of the original (unmutated) polypeptide.
- the constituent amino acids in the polypeptide may be either the D-form or the L-form, but the L-form is usually preferred unless otherwise specified.
- the polypeptide in the present invention may be a ligand peptide for G protein-coupled receptor protein, an amide or ester thereof, or a salt thereof, that is, a ligand polypeptide capable of binding to G protein-coupled receptor protein.
- an amide or an ester or a salt thereof specifically, for example, containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 44 or SEQ ID NO: 45.
- a polypeptide or an amide or an ester thereof or a salt thereof (hereinafter, may be simply referred to as a ligand polypeptide or a polypeptide).
- the G protein-coupled receptor protein is a receptor protein having a common structure having seven cell transmembrane domains, and most of them are conjugated guanine nucleotide binding proteins (guani proteins). It performs intracellular signal transduction through activation of ne nuc leot i de-binding protein).
- the amino acid sequence represented by SEQ ID NO: 44 includes the amino acid sequence represented by SEQ ID NO: 3, 18, or 32.
- the amino acid sequence represented by SEQ ID NO: 32 The amino acid sequence represented is mentioned.
- the amino acid sequence represented by SEQ ID NO: 45 preferably includes the amino acid sequence represented by SEQ ID NO: 6, 21 or 35, and particularly, the amino acid sequence represented by SEQ ID NO: 35 And an amino acid sequence represented by
- polypeptide in the present invention examples include all tissues of human warm-blooded animals (for example, guinea pig, rat, mouse, bush, hidge, magpie, monkey, etc.) (for example, pituitary gland, kidney, brain, kidney) , Liver, gonad, thyroid, gall bladder, bone marrow, adrenal gland, skin, muscle, lung, gastrointestinal tract, blood vessel, heart, etc.) or a polypeptide derived from a cell or the like.
- tissues of human warm-blooded animals for example, guinea pig, rat, mouse, bush, hidge, magpie, monkey, etc.
- tissues of human warm-blooded animals for example, guinea pig, rat, mouse, bush, hidge, magpie, monkey, etc.
- tissues of human warm-blooded animals for example, guinea pig, rat, mouse, bush, hidge, magpie, monkey, etc.
- pituitary gland for example, pituitary gland
- SEQ ID NO: 44 Or an amino acid sequence identical or substantially identical to the amino acid sequence represented by SEQ ID NO: 45, preferably represented by SEQ ID NO: 3, 18, or 32 or SEQ ID NO: 6, 21, 21 or 35 Ami Any amino acid sequence that is the same or substantially the same as the amino acid sequence may be used.
- an amino acid sequence represented by SEQ ID NO: 44 or SEQ ID NO: 45 preferably SEQ ID NO: 3, 18, or 32 or SEQ ID NO: 6, 21
- the amino acid sequence represented by SEQ ID NO: 44 or SEQ ID NO: 45 preferably SEQ ID NO: 3, 18 Or 32 or the amino acid sequence represented by SEQ ID NO: 6, 21 or 35 and about 50 to 99.9% (preferably 70 to 99.9%, more preferably 80 to 90%). -99.9%, more preferably 90-99.
- polypeptide having substantially the same activity as the polypeptide containing the amino acid sequence to be used examples include activities of the ligand polypeptide, such as receptor binding activity and signal transduction activity.
- activities of the ligand polypeptide such as receptor binding activity and signal transduction activity.
- substantially the same activity indicates that properties such as the receptor binding activity are the same. Therefore, the receptor binding activity may be insignificant, and the difference in molecular weight of the ligand polypeptide is not a problem.
- the polypeptides of the present invention also include these peptides due to non-essential amino acid sequence differences.
- the ligand polypeptide of the present invention, its production method and use are described in more detail below.
- the ligand polypeptide of the present invention specifically, for example, a polypeptide derived from a rat, mouse, human or mouse containing the amino acid sequence represented by SEQ ID NO: 44 or SEQ ID NO: 45 And the like.
- the third Xaa is Thr or A1a
- the fifth Xaa is Arg.
- G 1 n the 10th Xaa is I1e or Thr
- the 2nd Xaa is Thr or A1a
- the 2nd Xaa is G1y or Ser
- the 10th Xaa represents Thr or A1a
- the 11th Xaa represents G1y or Ser.
- ligand polypeptide of the present invention includes:
- amino acid sequence substituted with an acid (i) one or more and 15 or less, preferably 1 or more and 10 or less, more preferably 1 or more and 5 or less amino acids in the amino acid sequence represented by SEQ ID NO: 44 are other amino acids
- amino acids 1 to 15 amino acids, preferably 1 to 10 amino acids, more preferably 1 to 5 amino acids are added to the amino acid sequence represented by SEQ ID NO: 44 (insertion) Amino acid sequence, and
- ligand polypeptide of the present invention includes:
- a polypeptide containing an amino acid sequence having a modification in a constituent amino acid (particularly, its side chain) in the polypeptide of (V), (vi) or (vii), or an amide or ester thereof or a salt thereof Is also included.
- the ligand polypeptide of the present invention has the amino acid sequence (i) By intentionally or accidentally performing the substitution, deletion, addition, modification, or the like of (viii), the stable ligand polypeptide against heat or protease and the physiological activity of the ligand polypeptide are enhanced. It can be mutated (converted) to highly active ligand polypeptides.
- the ligand polypeptide or its amide, ester or salt thereof in the present invention also includes these mutant ligand polypeptides.
- the peptide is described as N-terminal (amino terminal) at the left end and C-terminal (carboxyl terminal) at the right end, according to the customary practice.
- Examples of the modification of the constituent amino acids in the polypeptide of the present invention include, for example, those in which the N-terminal side of G1n is cleaved in a living body and the G1n is pyroglutamine-oxidized.
- the polypeptide represented by SEQ ID NO: 44 or SEQ ID NO: 45 only one carboxyl group of the C-terminal amino acid residue usually has a hydroxyl group (—COOH) or carboxyl group. (—COO—), but the carboxyl group of the C-terminal amino acid residue may be an amide (_C ⁇ NH 2 ) or an ester (one COOR).
- R of the ester represented by -COOR methyl if example embodiment, Echiru, n- propyl, isopropyl or n- butyl etc.
- cyclopentyl, C 3 _ 8 cycloalkyl group such as cyclohexyl, phenyl, shed - C 6, such as naphthyl - 12 Ariru group, benzyl, phenyl 2 alkyl group such as phenethyl, Jifue two Lou C 2 _ 2 alkyl, such as benzhydryl, or ⁇ - naphthylmethyl etc.
- ⁇ - Nafuchiru C i _ 2 In addition to C 7 -i 4 aralkyl groups such as alkyl and the like, a bivaloyloxymethyl group widely used as an oral ester and the like can be mentioned.
- polypeptide of the present invention for example, the polypeptide represented by SEQ ID NO: 44 or SEQ ID NO: 45 has a carboxyl group or a propyloxylate other than at the C-terminal, those groups are amidated.
- an esterified polypeptide is also included in the polypeptide of the present invention. In this case, the ester is the same as, for example, the ester of the C-terminal amino acid residue described above.
- the carboxy of the C-terminal amino acid residue is used.
- Peptides in which the radical is an amide are preferred.
- a polypeptide having the amino acid sequence represented by SEQ ID NO: 3, 6, 18, 21, 32 or 35, wherein the carboxyl group at the C-terminal amino acid residue of the polypeptide is an amide is preferable. .
- a salt with a physiologically acceptable base for example, an alkali metal or the like
- an acid organic acid or inorganic acid
- a physiologically acceptable acid is used.
- Addition salts are preferred. Examples of such salts include salts with inorganic acids (eg, hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, etc.), and organic acids (eg, acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, etc.). Acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesulfonic acid, benzenesulfonic acid, etc.).
- inorganic acids eg, hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, etc.
- organic acids eg, acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, etc.
- the ligand polypeptide of the present invention can be produced by (i) a method for purifying the polypeptide from human or warm-blooded animal tissue or cells, and (ii) produced according to a known polypeptide synthesis method. You can also. Furthermore, it can also be produced by (iii) a method of culturing a transformant containing DNA encoding the polypeptide (described later).
- the ligand polypeptide is produced from human or warm-blooded animal tissues or cells
- the human or warm-blooded animal tissues or cells are homogenized, extracted with an acid or the like, and the extract is subjected to reverse phase chromatography. It can be purified and isolated by combining chromatography such as chromatography, ion exchange chromatography and affinity chromatography.
- the ligand polypeptide can also be produced according to a polypeptide synthesis method known per se.
- a method for synthesizing a peptide for example, any of a solid phase synthesis method and a liquid phase synthesis method may be used. That is, the desired peptide can be produced by condensing a partial peptide or amino acid capable of constituting a ligand polypeptide with the remaining portion, and removing the protecting group when the product has a protecting group.
- condensation methods and methods for removing protective groups include the methods described in the following 1 to 1.
- examples of the method for synthesizing the ligand polypeptide of the above (ii) include the following methods.
- a peptide synthesis resin suitable for amide formation may be used.
- a resin include chloromethyl resin, hydroxymethyl resin, benzhydrylamine resin, aminomethyl resin, 4-benzyloxybenzyl alcohol resin, 4-methylbenzhydrylamine resin, PAM resin, and 4-hydroxy resin.
- an amino acid having an ⁇ -amino group and a side chain functional group protected with a known suitable protecting group is condensed on the resin according to the sequence of the target peptide according to various known condensation methods. .
- the peptide is cleaved from the resin and various protecting groups are removed to obtain the desired polypeptide.
- various activating reagents that can be used for peptide synthesis can be used, and carbodiimides are particularly preferable.
- the carposimides include DCC, N, N'-diisopropylcarboimide, and N-ethyl-N '-(3-dimethylaminoprolyl) carbopimide.
- Activation by these involves adding the protected amino acid directly to the resin along with a racemization inhibitor additive (eg, HOB t) or pre-protecting the amino acid as a symmetric anhydride or HOB t ester or HOOB t ester.
- a racemization inhibitor additive eg, HOB t
- pre-protecting the amino acid as a symmetric anhydride or HOB t ester or HOOB t ester can be added to the resin after activation.
- Solvents used for activation of protected amino acids and condensation with resins include those usable in peptide condensation reactions. What is necessary is just to select suitably from a known solvent. Examples of the solvent include acid amides such as N, N-dimethylformamide, N, N-dimethylacetamide, N-methylpyrrolidone, halogenated hydrocarbons such as methylene chloride and chloroform, and trifluoroethanol.
- reaction temperature in the condensation reaction may be appropriately selected from a temperature range which can be used for a known peptide bond forming reaction, and is usually in a range of about 120: to 50 ° C.
- the activated amino acid derivative is usually used in a 1.5 to 4-fold excess.
- the degree of achievement of the condensation reaction can be confirmed by using a known ninhydrin reaction.As a result, when the condensation is insufficient, sufficient condensation can be performed by repeating the condensation reaction without removing the protecting group. It can be carried out. When sufficient condensation cannot be obtained even by repeating the reaction, the unreacted amino acid can be acetylated using acetic anhydride or acetylimidazole so as not to affect the subsequent reaction.
- the protecting group for the amino group of the amino acid used as a raw material in the synthesis of the peptide includes, for example, Z, Boc, tert-amyloxycarbonyl, isobornyloxycarbonyl, 4-methoxybenzyloxycarbonyl , CI-Z, Br-Z, adamantyloxycarboe, trifluoroacetyl, phthalyl, formyl, 2--2-phenylphenylsulfenyl, diphenylphosphinothioyl, and Fmoc.
- the protecting group of carboxyl group include the aforementioned Flip Bok 6 alkyl group, C 3 _ 8 cycloalkyl group, C 7 - 1 4 Ararukiru group, 2-Adamanchiru, 4-nitrobenzyl, 4-main Bok Kishibenjiru, 4 one And benzyl, phenacyl and benzyloxycarbonyl hydrazide, tert-butoxycarbonyl hydrazide, trityl hydrazide and the like.
- the hydroxyl groups of serine and threonine can be protected, for example, by esterification or etherification.
- Suitable groups for this esterification include, for example, lower (C ⁇ ) alkanol groups such as acetyl group, aroyl groups such as benzoyl group, and groups derived from carbonic acid such as benzyloxycarbonyl group and ethoxycarbonyl group. And so on.
- Examples of a group suitable for etherification include a benzyl group, a tetrahydroviranyl group, and a tert-butyl group.
- the protecting group of the phenolic hydroxyl group of tyrosine include B z to C 1 2 -B z 1, 2- two Torobenjiru, B r- Z, such as tert- butyl.
- the protecting groups for histidine imidazole include Tos, 4-methoxy-2,3,6-trimethylbenzenesulfonyl, DNP, benzyloxymethyl, Bum, Boc, Trt, Fmoc, etc. Is mentioned.
- Any peptide having a mutation in its amino acid sequence may be used as long as it has a secretory regulatory action.
- Examples of such a peptide include a peptide having an amino acid sequence in which 1 to 20 amino acids or less have been deleted from the peptide having the amino acid sequence represented by SEQ ID NO: 44.
- a peptide having the second to 31st amino acid sequences of the amino acid sequence represented by SEQ ID NO: 44 (b) a third peptide having the amino acid sequence represented by SEQ ID NO: 44 A peptide having the amino acid sequence from the 4th to the 31st amino acid sequence represented by SEQ ID NO: 44; (d) a peptide having the amino acid sequence from the 4th to 31st amino acid sequence represented by SEQ ID NO: 44; A peptide having the 5th to 31st amino acid sequence of the amino acid sequence shown, (e) a peptide having the 6th to 31st amino acid sequence of the amino acid sequence represented by SEQ ID NO: 44, (f) A peptide having the seventh through 31st amino acid sequences of the amino acid sequence represented by SEQ ID NO: 44, (g) the eighth through 31st amino acid sequences of the amino acid sequence represented by SEQ ID NO: 44 A peptide having (H) a peptide having the 9th to
- amino acid sequence represented by SEQ ID NO: 44 is more preferable as the amino acid sequence represented by SEQ ID NO: 44.
- SEQ ID NO: 3, 18 or 32 is the same as that exemplified for the amino acid sequence represented by SEQ ID NO: 44.
- a peptide having an amino acid sequence in which one or more and ten or less amino acids have been deleted from the peptide having the amino acid sequence represented by SEQ ID NO: 45 may be mentioned.
- a peptide having the 2nd to 20th amino acid sequence of the amino acid sequence represented by SEQ ID NO: 45 (b) an amino acid represented by SEQ ID NO: 45 A peptide having an amino acid sequence from the third to the 20th amino acid sequence of the sequence, (c) a peptide having the amino acid sequence of the fourth to 20th amino acid sequence of the amino acid sequence represented by SEQ ID NO: 45, d) a peptide having the 5th to 20th amino acid sequence of the amino acid sequence represented by SEQ ID NO: 45; (e) a peptide having the 5th to 20th amino acid sequence represented by SEQ ID NO: 45; A peptide having the 20th amino acid sequence, (f) a peptide having the 7th to 20th amino acid sequence of the amino acid sequence
- SEQ ID NO: 6 More preferable as the amino acid sequence represented by SEQ ID NO: 45, SEQ ID NO: 6, 21 or 35 also has a mutation in the amino acid sequence as exemplified for the amino acid sequence represented by SEQ ID NO: 45 You may.
- the ligand polypeptide in the present invention may be a fusion protein with another protein (eg, a known protein whose function or property is well known).
- the DNA encoding the ligand polypeptide in the present invention contains an amino acid sequence identical or substantially identical to the amino acid sequence represented by SEQ ID NO: 44 or SEQ ID NO: 45 in the present invention. Any substance may be used as long as it contains the nucleotide sequence encoding the polypeptide. Further, it may be any of genomic DNA, genomic DNA library, tissue / cell-derived cDNA, tissue / cell-derived cDNA library, and synthetic DNA.
- the vector used for the library may be any of bacteriophage, plasmid, cosmid, phagemid and the like. Alternatively, it can be directly amplified by RT-PCR (reverse transcription PCR) using an RNA fraction prepared from tissues and cells.
- a DNA encoding a polypeptide derived from rat whole brain or hypothalamus containing the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 15 is represented by SEQ ID NO: 2.
- DNA having a sequence is used.
- the 129th R represents G or A
- the 179th and 240th Ys represent C or T.
- Y at position 179 is C, it encodes the amino acid sequence represented by SEQ ID NO: 1
- Y at position 179 is T, it encodes the amino acid sequence represented by SEQ ID NO: 15.
- the DNA encoding the polypeptide derived from Escherichia coli containing the amino acid sequence represented by SEQ ID NO: 3, 4, 5, 6, 7 or 8 includes SEQ ID NO: 9, 10, 11, 12, 13 Or a DNA having the base sequence represented by 14 It is.
- the 63rd R of SEQ ID NO: 9, 10, 11 and the 29th R of SEQ ID NO: 12, 13, 14 represent G or A.
- the DNA encoding the rat-derived polypeptide represented by SEQ ID NO: 8, 18, 19, 20, 21, 22, or 23 includes SEQ ID NOs: 17, 24, 25, 26, 17, DNA having a base sequence represented by 28 or 29 is used.
- DNA encoding the human-derived polypeptide represented by SEQ ID NO: 30, 32, 33, 34, 35, 36 or 37, SEQ ID NO: 31, 38, 39, 40, 41, 42 or 43 DNA having the represented nucleotide sequence is used.
- a mouse polypeptide containing the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 15, a rat polypeptide containing the amino acid sequence represented by SEQ ID NO: 16, or SEQ ID NO: For example, 6 to 90 (preferably 6 to 60, more preferably 9 to 30) DNAs encoding a human polypeptide having the amino acid sequence represented by 30 (More preferably 12 or more and 30 or less)) is also preferably used as a DNA detection probe.
- DNA encoding the polypeptide of the present invention can also be produced by the following genetic engineering techniques.
- Cloning (cloning) of DNA that completely encodes the polypeptide of the present invention may be performed according to the following method. That is, (1) a DNA having a partial base sequence of the polypeptide is synthesized, and using this as a primer, a DNA encoding the polypeptide is completely amplified by PCR, or (2) cDNA or Is a DNA library obtained by incorporating genomic DNA or a DNA fragment thereof into an appropriate vector, for example, a DNA library obtained by labeling with a DNA fragment having a part or the entire region of the ligand polypeptide or a synthetic DNA. Sorting may be performed by performing hybridization. The hybridization method is described, for example, in Molecular Cloning (2nd ed .; J. Sambrook et al., Cold Spring Harbor). Lab. Press, 1989). When a commercially available DNA library is used, the method may be performed according to the method described in the attached instruction manual.
- the DNA encoding the cloned polypeptide may be used as it is, or may be used after digestion with a restriction enzyme or addition of linker DNA if desired.
- the DNA may have ATG as a translation initiation codon at the 5 'end and TAA, TGA or TAG as a translation stop codon at the 3' end. These translation initiation codon and translation termination codon can also be added using a suitable synthetic DNA adapter.
- An expression vector containing a DNA having a nucleotide sequence encoding the polypeptide includes, for example, (1) cutting out a target DNA fragment from a DNA containing the DNA encoding the polypeptide of the present invention; It can be produced by ligating a DNA fragment downstream of the promoter sequence in a known suitable expression vector.
- the vector include a plasmid derived from E.
- coli eg, pBR322, pBR325, pUC12, pUC13
- Bacillus subtilis eg, pUB110, DTP5, pC194
- yeast eg, , PSH19, pSH15
- bacteriophages such as ⁇ phage
- animal viruses such as retrovirus, vaccinia virus, and baculovirus.
- any promoter can be used as long as it functions properly in a host used for expression of the gene encoding the desired polypeptide.
- the host used for the transformation is Escherichia sp.
- the host is Bacillus sp.
- yeast such as SP01 promoter overnight, SP02 promoter, penP promoter, etc., PH05 promoter overnight, PGK promoter, GAP promoter evening, ADH promoter overnight, etc. are preferable.
- it encodes the desired polypeptide.
- Enhansa In order to efficiently express such genes, it is preferable to use Enhansa.
- a signal sequence suitable for the host is added to the N-terminal side of the polypeptide or its partial peptide.
- the host is a bacterium belonging to the genus Escherichia, an alkaline phosphatase signal sequence, a ⁇ mpA signal sequence, etc.
- the host is a bacterium belonging to the genus Bacillus, a human amylase signal sequence, a subtilisin signal sequence, etc.
- yeast the mating factor ⁇ signal sequence, invertase signal sequence, etc.
- the host is an animal cell, for example, the insulin signal sequence, ⁇ -interferon signal sequence, antibody molecule signal An array etc. can be used respectively.
- a transformant is produced using the vector containing the polypeptide or the DNA encoding the partial peptide thus constructed.
- Examples of the host for transformation include known Escherichia bacteria, Bacillus bacteria, yeast, insects, animal cells, and the like. .
- Escherichia examples include, for example, Escherichia coli K12 ⁇ DH1 [Procedings of the National Academy of Sciences ”Proc. Natl. Acad. Sci. USA), Vol. 60, p. 160 (1968)], JM 103 [Nucleic Acids Research], Vol. 9, p. 309 (1981) :), JA221 (Journal of Molecular Biology), Vol. 120, p. 517 (1978)], HB 101 (Journal of Molecular Biology, Vol. 41, 459 (1969)] and C600 [Genetics, Vol. 39, p. 440 (1954)].
- Bacillus subtilis MI114 Gene, Vol. 24, p. 255 (1983)
- 207-21 Journal of "Ob 'Bio”. Chemistry (Journal of Biochemistry), Vol. 95, p. 87 (1984)].
- yeast examples include Saccharomyces cerevisiae AH22, AH22 R—, NA87-11A, DKD-5D, and 20B. I-12 and the like.
- insects examples include silkworm larvae [Maeda et al., Nature, Vol. 315, p. 592 (1985)].
- animal cells examples include monkey cells COS-7, Vero, Chinese hamster cells CHO, DHFR gene-deficient Chinese hamster cells CH ⁇ (dhfr-CHO cells), mouse L cells, mouse myeloma cells, and human FL cells. No.
- Transformation of Bacillus spp. May be performed, for example, according to the method described in Molecular 'and General Genetics, Vol. 168, p. 111 (1979).
- Transformation of insect cells may be performed, for example, according to the method described in Bio / Technology, Vol. 6, page 47 (1988).
- Transformation of animal cells is performed, for example, according to the method described in Virology, Vol. 52, p. 456 (1973).
- a liquid medium which contains a carbon source, a nitrogen source, an inorganic substance, and the like necessary for growth of the transformant.
- the carbon source include glucose, dextrin, soluble starch, and sucrose.
- the nitrogen source include ammonium salts, nitrates, corn chip lica, peptone, casein, meat extract, soybean meal, Inorganic or organic substances such as potato extract Examples include calcium chloride, sodium dihydrogen phosphate, magnesium chloride, and the like.
- yeast extract, vitamins, growth promoting factors and the like may be added to the medium as needed.
- the pH of the medium may be any pH as long as the transformant can grow, but the pH is usually preferably about 5 to 8.
- Examples of a medium for culturing Escherichia bacteria include, for example, an M9 medium containing glucose and casamino acids (Miller, Journal of Experiments in Molecular Genetics) , 431, Cold Spring Harbor Laboratory, New York 1972]. If necessary, a drug such as 3 / 3-indolylacrylic acid may be added to the medium and cultured in order to make the promoter work efficiently.
- the host is a bacterium belonging to the genus Escherichia
- the cultivation is usually performed at about 15 to 43 ° C for about 3 to 24 hours, and if necessary, aeration and stirring may be added.
- the cultivation is usually carried out at about 30 to 40 ° C for about 6 to 24 hours, and if necessary, aeration and stirring may be added.
- the pH of the medium is adjusted to about 5-8.
- the cultivation is usually performed at about 2 Ot to 35 ° C for about 24 to 72 hours, and if necessary, aeration and agitation can be added.
- the culture medium When culturing a transformant in which the host is an insect, the culture medium was immobilized in Grace's Insect Medium (Grace, TCC, Nature, Vol. 195, p. 788 (p. 1962)). Those to which additives such as serum are appropriately added are used.
- the pH of the medium is preferably adjusted to about 6.2 to 6.4. Cultivation is usually performed at about 27 ° C for about 3 to 5 days, and if necessary, aeration and stirring can be applied.
- the culture medium is, for example, about 5 to MEM medium containing 20% fetal bovine serum [Science, Vol. 122, p. 501 (1952)], DMEM medium [Virology, Vol. 8, p. 396 (1959)], RPMI 1640 medium [Journal of the American Medical Association, Vol. 199, p. 519 (1967)], 1999 medium [Procedure of the America] ⁇ Society ⁇ One 'The' Noological ⁇ Meisin (Proceeding of the Society for the Biological Medicine), Vol. 73, p. 1 (1950)].
- the pH is about 6-8.
- the cultivation is usually performed at about 30 ° C to 40 ° C for about 15 to 60 hours, and if necessary, aeration and stirring can be applied.
- the polypeptide can be separated and purified from the above culture (culture solution and cultured cells or cultured cells), for example, by the following method.
- the cells or cells are collected by a known method, suspended in an appropriate buffer, and then subjected to a known ultrasonic treatment. After disrupting the cells or cells by lysozyme treatment and / or freeze-thawing treatment, the target polypeptide or its partial peptide can be obtained as an extract by known centrifugation, filtration, etc. .
- the buffer may contain a protein denaturant such as urea or guanidine hydrochloride, or a surfactant such as Triton X-100 (registered trademark: hereinafter sometimes abbreviated as TM) such as Triton X-100 (Wako Pure Chemical Industries, Ltd.). You may add and use a sexual agent as needed.
- the cultured cells or cultured cells and the culture supernatant can be separated by a known method to obtain a culture supernatant.
- the polypeptide contained in the obtained culture supernatant or extract can be purified by appropriately combining known separation and purification methods.
- These known separation and purification methods include (1) a method using solubility such as salting-out and solvent precipitation, (2) dialysis, ultrafiltration, gel filtration, and SDS-polyacrylamide gel electrolysis. Methods that mainly use the difference in molecular weight, such as the swimming method, (3) Methods that use the difference in charge such as ion-exchange chromatography, and (4) Use specific affinity such as affinity chromatography. Method, (5) Reversed-phase high-performance liquid chromatograph And (6) a method using a difference in isoelectric point such as isoelectric focusing or chromatophoresis.
- the polypeptide When the polypeptide is obtained as a free form, it can be converted to a salt by a method known per se or a method analogous thereto, and conversely, when the polypeptide is obtained as a salt, a method known per se or a method analogous thereto Can be converted into a free form or another salt.
- an appropriate protein-modifying enzyme is allowed to act on the polypeptide according to a known method to add any modification to the polypeptide or to partially modify the sequence in the polypeptide. Can also be removed.
- the protein-modifying enzyme include tribcine, chymotrypsin, arginyl endopeptidase, protein kinase, glycosidase and the like. .
- the activity of the mutant polypeptide thus obtained can be measured by a binding experiment with Receptor Yuichi or the Enzymimnoassay method using a specific antibody.
- the ligand polypeptide of the present invention has a regulating effect on oxytocin secretion, that is, a promoting and suppressing effect on oxytocin secretion. That is, since the ligand polypeptide of the present invention has an activity of promoting oxytocin secretion, as will be apparent from the examples described later, it can be used as an agent for preventing and treating various diseases related to auxitocin secretion deficiency.
- the ligand polypeptide of the present invention has a strong affinity for its receptor protein, and as the dose increases, desensitization to oxytocin secretion occurs, resulting in oxytocin secretion. It also has the effect of suppressing. In this case, it can be used as an agent for preventing and treating various diseases associated with auxitocin hypersecretion.
- the ligand polypeptide of the present invention may be used as an oxytocin secretion promoter as a weak labor, laxative hemorrhage, placental delivery, uterine remodeling failure, cesarean section, artificial abortion, milk stasis, labor induction, lactation insufficiency. , Infertility, dysmenorrhea, miscarriage, post-traumatic stress syndrome, etc., preferably weak labor, lax hemorrhage, placental delivery, incomplete uterine reconstruction, cesarean section, abortion, milk stasis, etc.
- the ligand polypeptide of the present invention may be used as an oxytocin secretion inhibitor as an overactive labor, tonic uterine contraction, fetal asphyxia, uterine rupture, cervical laceration, preterm birth, Prader-Wi 11i syndrome, dysmenorrhea
- amelioration of various diseases related to secretion of oxytocin such as overwork labor, tonic contractions, fetal asphyxia, uterine rupture, ruptured tubules, premature birth, and the Prader-Wi11i syndrome group.
- the ligand polypeptide of the present invention can be used as a test drug for examining oxytocin secretion function, or as an animal drug such as a milk secretion promoter for livestock mammals such as cattle, goats and bush. It is useful, and is also expected to be applied to production of useful substances by producing useful substances in the livestock mammals and secreting them into milk.
- the polypeptide of the present invention When used as the above-mentioned medicament or veterinary drug, it may be carried out according to conventional means. For example, sterile solutions or suspensions in tablets or capsules, capsules, elixirs, microcapsules, etc., as needed, orally, or with water or other pharmaceutically acceptable liquids It can be used parenterally in the form of injections such as liquids.
- the polypeptide or a salt thereof may be combined with a physiologically acceptable carrier, flavoring agent, excipient, vehicle, preservative, stabilizer, binder and the like in a unit dosage form required for generally accepted pharmaceutical practice. It can be manufactured by mixing. The amount of active ingredient in these preparations is such that a suitable dosage in the specified range can be obtained.
- Additives that can be incorporated into tablets, capsules, etc. include, for example, binders such as gelatin, corn starch, tragacanth gum, gum arabic, excipients such as crystalline cellulose, corn starch, gelatin, alginic acid, etc.
- binders such as gelatin, corn starch, tragacanth gum, gum arabic
- excipients such as crystalline cellulose, corn starch, gelatin, alginic acid, etc.
- a leavening agent such as magnesium stearate
- a sweetener such as sucrose, lactose or saccharin
- a flavoring agent such as peppermint, cocoa oil or cherry, and the like
- a liquid carrier such as oils and fats can be further contained in the above-mentioned type of material.
- Sterile compositions for injection are prepared according to standard pharmaceutical manufacturing methods, such as dissolving or suspending the active substance in vehicles such as water for injection, and naturally occurring vegetable oils such as sesame oil
- aqueous liquids for injection examples include physiological saline, isotonic solutions containing glucose and other adjuvants (eg, D-sorbitol, D-mannitol, sodium chloride, etc.).
- Agents such as alcohols (eg, ethanol), polyalcohols (eg, propylene glycol, polyethylene glycol), and nonionic surfactants (eg, polysorbate 80 (TM), HCO-50).
- TM polysorbate 80
- sesame oil and soybean oil which may be used in combination with solubilizing agents such as benzyl benzoate and benzyl alcohol, etc.
- buffering agents eg, phosphate buffer, sodium acetate buffer
- painless Agent for example, benzalkonium chloride, proforce hydrochloride, etc.
- stabilizer for example, human serum albumin , Polyethylene glycol
- a preservative e.g., benzyl alcohol, phenol
- the preparations obtained in this way are safe and low toxic, and can be used, for example, in humans, mammals (eg, mice, rats, guinea pigs, egrets, higgs, bushus, dogs, cats, dogs, monkeys, baboons, Chimpanzee).
- the dose of the polypeptide in the present invention varies depending on the symptoms and the like. However, in the case of oral administration, in general, for a pregnant woman with a labor pain at the time of childbirth (with respect to a body weight of 60 kg), the dose is usually about 0 at a time. 1 to; L 00 mg, preferably about 1.0 to 50 mg, more preferably about 1.0 to 2 Omg.
- the dosage for each dose may vary depending on the subject, symptoms, and administration method.
- pregnant women with minimal labor during childbirth for 6 kg of body weight
- about 0.01 to 3 Omg, preferably about 0 :! to about 2 Omg, more preferably about 0.1 to 1 Omg may be administered by intravenous injection at a time.
- the dose can be administered in terms of weight per 60 kg.
- the G protein-coupled receptor protein (hereinafter sometimes simply referred to as receptor protein) or ligand polypeptide used in the present invention is prepared, for example, according to WO 96/05302 or WO 97/24436. can do.
- an oxytocin secretion regulator comprising a compound or a salt thereof that alters the binding property of the ligand polypeptide of the present invention to the receptor protein of the present invention and the receptor protein and the use thereof Describe.
- a compound that changes the binding property of the ligand polypeptide of the present invention to the receptor protein of the present invention and the receptor protein or a salt thereof promotes the function of the ligand polypeptide of the present invention (eg, oxytocin secretion). Or a salt thereof, and a compound or a salt thereof that inhibits the function of the ligand polypeptide of the present invention (eg, oxytocin secretion).
- a compound or a salt thereof that promotes the oxotocin secretion activity of the ligand polypeptide of the present invention includes: As a cytosine secretagogue, weak labor, lax hemorrhage, placental delivery, uterine remodeling failure, cesarean section, artificial abortion, milk stasis, labor induction, lactation insufficiency, infertility, dysmenorrhea, miscarriage, trauma Post-stress syndrome, etc., preferably weak labor, lax hemorrhage, placental delivery, uterine remodeling failure, cesarean section, artificial abortion, milk stasis, etc., particularly preferably faint labor, lax hemorrhage, placental release, uterus It can be used as a medicine for improving,
- a compound or a salt thereof that inhibits the oxytocin secretion action of the ligand polypeptide of the present invention may be used for overwork labor, tonic contraction, fetal asphyxia, uterine rupture, tubal laceration, preterm birth, Prader-Willli syndrome, As dysmenorrhea, preferably overwork labor, ankylosing contractions, fetal asphyxia, uterine rupture, cervical laceration, preterm birth, improvement of the Prader-Wi 11i syndrome group, etc. Can be used.
- the ligand polypeptide of the present invention is useful as a reagent for screening a compound or a salt thereof that promotes or inhibits the function of the ligand polypeptide of the present invention.
- Compounds or salts thereof that promote or inhibit the function of the ligand polypeptide of the present invention include, for example, G protein-coupled receptor protein [eg, phGR3, UHR-1 and the like (WO966705302). , WO97 / 24344)) and a compound that alters the binding property to the ligand polypeptide of the present invention. I can get it.
- G protein-coupled receptor protein eg, phGR3, UHR-1 and the like (WO966705302). , WO97 / 24344)
- I can get it.
- the screening method is described below.
- G protein-coupled receptor protein eg, phGR3, UHR-1, etc. (WW96 / 05302, WO 97/24436)
- An expression system is constructed, and a receptor protein binding system using the expression system is used.
- a compound eg, phGR3, UHR-1, etc. (WO 96/05302, WO 97/24436)
- a G protein-coupled receptor protein eg, phGR3, UHR-1, etc.
- Peptides, proteins, non-peptidic compounds, synthetic compounds, fermentation products, etc. or salts thereof can be efficiently screened.
- Such compounds include (1) cell stimulatory activity via G protein-coupled receptors (eg, arachidonic acid release, acetylcholine release, intracellular Ca 2+ release, intracellular cAMP production, intracellular cGMP production (2) a compound having an activity of promoting or inhibiting inositol phosphate production, cell membrane potential fluctuation, intracellular protein phosphorylation, activation of c-fos, decrease of PH, etc .; (3) a compound that enhances the binding force between the ligand polypeptide of the present invention and a G protein-coupled receptor protein, (4) a compound that does not have Includes compounds that decrease the binding force between the ligand polypeptide and the G protein-coupled receptor protein.
- G protein-coupled receptors eg, arachidonic acid release, acetylcholine release, intracellular Ca 2+ release, intracellular cAMP production, intracellular cGMP production
- the present invention relates to (i) contacting a receptor protein or a salt thereof with a ligand polypeptide or a salt thereof of the present invention; (II) a receptor protein or a salt thereof; and a ligand polypeptide of the present invention or a salt thereof.
- a method for screening the salt is provided.
- the screening method of the present invention is characterized in that, in the cases (i) and (ii), for example, the amount of a ligand bound to the receptor protein, the cell stimulating activity, and the like are measured and compared. .
- the labeled ligand polypeptide of the present invention or a salt thereof is treated with a receptor protein or the like. And a labeled ligand polypeptide of the present invention or a salt thereof when the labeled ligand polypeptide of the present invention or a salt thereof and a test compound are brought into contact with the receptor protein of the present invention or the like. The amount of binding of the salt to the receptor protein or the like is measured and compared, and the compound or the salt thereof that alters the binding property between the ligand polypeptide or the salt thereof and the receptor protein or the like according to the present invention. How to screen,
- the receptor protein or the like used in the screening method of the present invention may be any as long as it contains the aforementioned receptor protein or the like, but may contain the receptor protein or the like.
- Cell membrane fractions of mammalian organs are preferred.
- human-derived receptor proteins expressed in large amounts using recombinants were used for screening.
- White matter and the like are suitable.
- the production of the receptor protein and the like is preferably carried out by expressing the DNA encoding the receptor in mammalian cells and insect cells.
- Complementary DNA is used for the DNA fragment encoding the target protein, but is not necessarily limited to this.
- a gene fragment or a synthetic DNA may be used.
- the DNA fragments In order to introduce DNA fragments encoding the Recebu Yuichi protein into host animal cells and express them efficiently, the DNA fragments must be expressed in a nuclear polyhedrosis virus belonging to baculovirus using insects as a host.
- NP V polyhedrin promoters
- SV40-derived promoters SV40-derived promoters
- retrovirus promoters metamouth thionine promoters
- human heat shock promoters cytomegalovirus promoters
- SR promoters SR promoters.
- the quantity and quality of the expressed receptor can be determined by a method known per se. For example, according to the method described in the literature [Nambi, P. et al., The Journal of Biological Chemistry (J. Biol. Chem.), 267, pp. 19555-19559, 1992]. Can be.
- the protein containing the receptor protein or the like may be the receptor protein or the like purified according to a method known per se, or a cell containing the receptor protein or the like may be used. Alternatively, a membrane fraction of cells containing the receptor protein or the like may be used.
- the cells when cells containing the receptor protein of the present invention or the like are used, the cells may be immobilized with daltaraldehyde, formalin, or the like.
- the immobilization method can be performed according to a method known per se.
- the cell containing the receptor protein or the like refers to a host cell that has expressed the receptor protein or the like, and the host cell is preferably Escherichia coli, Bacillus subtilis, yeast, insect cells, animal cells, or the like.
- the cell membrane fraction refers to a fraction abundant in cell membrane obtained by disrupting cells and then obtained by a method known per se.
- Methods for crushing cells include crushing cells with a Potter-E1Vehj em-type homogenizer, crushing using a Warlinda blender or polytron (manufactured by Kinematica), crushing using ultrasonic waves, French crushing. Crushing by ejecting cells from a thin nozzle while adding pressure with a loess.
- centrifugal fractionation methods such as differential centrifugation and density gradient centrifugation are mainly used.
- the cell lysate is centrifuged at a low speed (500 rpm to 3000 rpm) for a short time (typically about 1 to 10 minutes), and the supernatant is further spun at a higher speed (15000 rpm to 30000 rm) for usually 30 minutes. Centrifuge for ⁇ 2 hours, and use the resulting precipitate as the membrane fraction.
- the membrane fraction contains a large amount of expressed receptor proteins and membrane components such as cell-derived phospholipids and membrane proteins.
- the amount of receptor protein in cells or membrane fractions containing the receptor protein or the like is preferably 10 3 to 10 8 molecules per cell, and more preferably 10 5 to 10 7 molecules per cell. It is.
- an appropriate receptor protein protein fraction and a labeled ligand polypeptide of the present invention are used. Or its salt is required.
- the receptor protein fraction a natural receptor protein fraction or a recombinant receptor protein fraction having the same activity as the receptor protein fraction is desirable.
- equivalent activity refers to equivalent ligand binding activity, signal transduction action and the like.
- the labeled ligand a labeled ligand, a labeled ligand analog compound and the like are used. For example, ligands labeled with [ 3 H], [ 125 I], [ 14 C], [ 35 S] and the like are used.
- a receptor protein sample by suspending it in a buffer suitable for screening.
- the buffer may be any buffer as long as it does not inhibit the binding between the ligand and the receptor protein, such as a phosphate buffer of pH 4 to 10 (preferably pH 6 to 8) and a buffer of tris-monohydrochloride.
- CHAPS, Tween- Surfactants such as 80 TM (Kaoichi Atlas), digitonin, and dexcholate can also be added to the buffer.
- a protease inhibitor such as PMS F, leptin, E-64 (manufactured by Peptide Research Laboratories), and peptide suptin can be added to suppress the degradation of the receptor and the ligand by the protease.
- PMS F Propeptide Research Laboratories
- E-64 manufactured by Peptide Research Laboratories
- peptide suptin can be added to suppress the degradation of the receptor and the ligand by the protease.
- NBS non-specific binding
- the reaction is carried out at about 0 ° C to 5O :, preferably about 4-371: for about 20 minutes to 24 hours, preferably for about 30 minutes to 3 hours.
- filter with a glass fiber filter or the like wash with an appropriate amount of the same buffer, and measure the radioactivity remaining on the glass fiber filter with a liquid scintillation counter or an oven.
- the specific binding amount (B-NSB) force A test compound having 50% or less can be selected as a candidate substance having a competitive inhibitory ability.
- a cell stimulating activity mediated by a receptor protein eg, arachidonic acid release, acetylcholine Release, Intracellular Ca release, Intracellular cAMP production, Intracellular cGMP production, Inositol phosphate production, Cell membrane potential fluctuation, Intracellular protein phosphorylation, Activation of c-fos, Decrease in pH, etc.
- a cell stimulating activity mediated by a receptor protein eg, arachidonic acid release, acetylcholine Release, Intracellular Ca release, Intracellular cAMP production, Intracellular cGMP production, Inositol phosphate production, Cell membrane potential fluctuation, Intracellular protein phosphorylation, Activation of c-fos, Decrease in pH, etc.
- Activity or inhibitory activity can be measured using a known method or a commercially available measurement kit.
- cells containing a receptor protein or the like are cultured in a multiwell plate or the like. Before performing the screening, replace the cells with a fresh medium or an appropriate buffer that is not toxic to cells, add test compounds, etc., incubate for a certain period of time, and then extract the cells or collect the supernatant.
- the products produced are quantified according to the respective method.
- a substance for example, arachidonic acid
- an inhibitor for the degrading enzyme may be added to perform the assay.
- activities such as cAMP production suppression can be detected as a production suppression effect on cells whose basic production has been increased with forskolin or the like.
- cells expressing an appropriate receptor protein are required.
- a cell line having the natural receptor protein of the present invention or the like a cell line expressing the above-mentioned recombinant receptor protein or the like is desirable.
- test compounds for example, peptides, proteins, non-peptidic compounds, synthetic compounds, fermentation products, cell extracts, plant extracts, animal tissue extracts, etc. are used, and these compounds are novel compounds. Or a known compound.
- the kit for screening a compound or a salt thereof that changes the binding property between the ligand polypeptide of the present invention and Recept Yuichi protein or the like may be a cell containing Recept Yuichi protein, etc., Recept Yuichi protein, etc., or Recept Yuichi protein. And those containing a membrane fraction of cells containing the same.
- screening kit of the present invention examples include the following. 1. Screening reagent
- the ligand of the present invention is dissolved in PBS containing 0.1% Pserum serum albumin (manufactured by Sigma) so as to be ImM, and the resulting mixture is stored at 1-20.
- oxytocin secretion regulator When a compound or a salt thereof that changes the binding between the ligand polypeptide of the present invention and the receptor protein of the present invention for the receptor protein of the present invention or a salt thereof is used as the above-mentioned oxytocin secretion regulator, it is carried out according to a conventional method. do it. For example, tablets, capsules, elixirs, microcapsules, and the like, sugar-coated as required, orally, or aseptic solution or suspension in water or other pharmaceutically acceptable liquids It can be used parenterally or as nasal drops in the form of injections such as liquids.
- a physiologically acceptable carrier or flavor of the compound or a salt thereof can be prepared by mixing the compound with excipients, excipients, vehicles, preservatives, stabilizers, binders and the like in the unit dosage form generally required for accepted pharmaceutical practice.
- the amount of the active ingredient in these preparations is such that a suitable dosage in the specified range can be obtained.
- Additives that can be incorporated into tablets, capsules, etc. include, for example, binders such as gelatin, corn starch, tragacanth gum, gum arabic, excipients such as crystalline cellulose, corn starch, gelatin, alginic acid, etc.
- binders such as gelatin, corn starch, tragacanth gum, gum arabic
- excipients such as crystalline cellulose, corn starch, gelatin, alginic acid, etc.
- a leavening agent such as magnesium stearate
- a sweetener such as sucrose, lactose or saccharin
- a flavoring agent such as peppermint, cocoa oil or cherry are used.
- a liquid carrier such as an oil or fat can be further contained in the above-mentioned type of material.
- Sterile compositions for injection should be treated according to standard pharmaceutical manufacturing methods, such as by dissolving or suspending the active substance in vehicles such as water for injection, and naturally occurring vegetable oils such as sesame
- aqueous liquids for injection include physiological saline, isotonic solutions containing glucose and other adjuvants (eg, D-sorbitol, D-mannitol, sodium chloride, etc.).
- Agents such as alcohols (eg, ethanol), polyalcohols (eg, propylene glycol, polyethylene glycol), nonionic surfactants (eg, polysorbate 80 (TM), HCO-50) .
- the oily liquid include sesame oil and soybean oil, which may be used in combination with solubilizers such as benzyl benzoate and benzyl alcohol.
- buffering agents eg, phosphate buffer, sodium acetate buffer
- soothing agents eg, benzalkonium chloride, proforce hydrochloride, etc.
- stabilizers eg, human serum albumin, polyethylene glycol, etc.
- Preservatives eg, benzyl alcohol, phenol, etc.
- antioxidants eg, antioxidants and the like.
- the preparations obtained in this way are safe and low toxic, and can be used, for example, in humans and mammals (eg, mice, rats, guinea pigs, egrets, sheep, sheep, bush, dogs, cats, Dogs, monkeys, chimpanzees, etc.).
- mammals eg, mice, rats, guinea pigs, egrets, sheep, sheep, bush, dogs, cats, Dogs, monkeys, chimpanzees, etc.
- the dosage of the oxytocin secretion regulator containing the above compound or its salt may vary depending on the symptoms, etc., but when administered orally, it is generally used in pregnant women with a labor that is weak at birth (for a body weight of 60 kg). Is usually about 0.1 to 100 mg, preferably about 1.0 to 50 mg, more preferably about 1.0 to 2 Omg of a compound having an oxytocin secretion promoting action at one time. . In the case of parenteral administration, the single dose varies depending on the subject of administration, the symptoms ⁇ , the administration method, etc.
- a compound having an oxytocin secretion-promoting action at a time or a salt thereof is usually used in an amount of about 0.01 to 3 Omg, preferably about 0.1 to 2 Omg, more preferably about 0.1 to 2 Omg.
- About 1 Omg may be administered by intravenous injection. In the case of other animals, the amount can be administered in terms of the body weight of 60 kg.
- sequence numbers in the sequence listing in the present specification indicate the following sequences.
- FIG. 3 shows the full-length amino acid sequence of the ligand polypeptide derived from the hypothalamus contained in pBO3.
- 1 shows the entire nucleotide sequence of a hypothalamus-derived ligand polypeptide cDNA.
- FIG. 2 shows the amino acid sequence of a hypothalamus-derived ligand polypeptide. This corresponds to the amino acid sequence of positions 23 to 53 of SEQ ID NO: 1.
- FIG. 2 shows the amino acid sequence of a hypothalamus-derived ligand polypeptide. This corresponds to the amino acid sequence of positions 23 to 54 of SEQ ID NO: 1.
- FIG. 2 shows the amino acid sequence of a hypothalamus-derived ligand polypeptide. This corresponds to the amino acid sequence of positions 23 to 55 of SEQ ID NO: 1.
- [SEQ ID NO: 6] 2 shows an amino acid sequence of a hypothalamus-derived ligand polypeptide. This corresponds to the amino acid sequence of positions 34 to 53 of SEQ ID NO: 1.
- FIG. 2 shows the amino acid sequence of a hypothalamus-derived ligand polypeptide. This corresponds to the 34th to 54th amino acid sequence of SEQ ID NO: 1.
- FIG. 2 shows the amino acid sequence of a hypothalamus-derived ligand polypeptide. This corresponds to the 34th to 55th amino acid sequence of SEQ ID NO: 1.
- ⁇ ⁇ Shows the nucleotide sequence of DNA encoding the hypothalamus-derived ligand polypeptide (SEQ ID NO: 3).
- ⁇ Shows the nucleotide sequence of the DNA encoding the hypothalamus-derived ligand polypeptide (SEQ ID NO: 4).
- ⁇ Shows the nucleotide sequence of the DNA encoding the hypothalamus-derived ligand polypeptide (SEQ ID NO: 5).
- ⁇ Shows the nucleotide sequence of the DNA encoding the hypothalamus-derived ligand polypeptide (SEQ ID NO: 6).
- ⁇ Shows the nucleotide sequence of the DNA encoding the hypothalamus-derived ligand polypeptide (SEQ ID NO: 7).
- ⁇ Shows the nucleotide sequence of DNA encoding hypothalamus-derived ligand polypeptide (SEQ ID NO: 8).
- 1 shows the full-length amino acid sequence of a ligand polypeptide derived from a rice genome.
- [SEQ ID NO: 16] 1 shows the full-length amino acid sequence of a rat ligand polypeptide.
- 1 shows the entire nucleotide sequence of rat type ligand polypeptide cDNA.
- 1 shows the amino acid sequence of a rat ligand polypeptide. This corresponds to the 22nd to 52nd amino acid sequence of SEQ ID NO: 16.
- 1 shows the amino acid sequence of a rat ligand polypeptide. This corresponds to the 22nd to 53rd amino acid sequence of SEQ ID NO: 16.
- 1 shows the amino acid sequence of a rat ligand polypeptide. This corresponds to the 22nd to 54th amino acid sequence of SEQ ID NO: 16.
- 1 shows the amino acid sequence of a rat ligand polypeptide. This corresponds to the amino acid sequence at positions 33 to 52 of SEQ ID NO: 16.
- 1 shows the amino acid sequence of a rat ligand polypeptide. This corresponds to the amino acid sequence at positions 33 to 53 of SEQ ID NO: 16.
- 1 shows the amino acid sequence of a rat ligand polypeptide. This corresponds to the 33rd to 54th amino acid sequence of SEQ ID NO: 16.
- 1 shows the full-length amino acid sequence of a human ligand polypeptide.
- 1 shows the entire nucleotide sequence of human ligand polypeptide cDNA.
- 1 shows the amino acid sequence of a human ligand polypeptide. This corresponds to the amino acid sequence of positions 23 to 53 of SEQ ID NO: 30.
- 1 shows the amino acid sequence of a human ligand polypeptide. This corresponds to the 23rd to 54th amino acid sequence of SEQ ID NO: 30.
- 1 shows the amino acid sequence of a human ligand polypeptide. This corresponds to the amino acid sequence of positions 23 to 55 of SEQ ID NO: 30.
- 1 shows the amino acid sequence of a human ligand polypeptide. This corresponds to the amino acid sequence of positions 34 to 53 of SEQ ID NO: 30.
- 1 shows the amino acid sequence of a human ligand polypeptide. This corresponds to the amino acid sequence of positions 34 to 55 of SEQ ID NO: 30.
- FIG. 1 shows the amino acid sequence of the ligand polypeptide of the present invention.
- the eleventh X aa is A 1 a or Th r
- the eleventh X a a is G 1 y or S er
- the second X a a is H, G 1 y, or G 1 y
- Example 1 shows the amino acid sequence of the ligand polypeptide of the present invention.
- the 10th Xaa represents Thr or A1a
- the 1st Xaa represents G1y or Ser.
- rat organs male Wistar rats were decapitated, each organ was taken out, the tissue weight was measured, and immediately frozen with liquid nitrogen.
- PrRP (19 P 2-L 31) To extract PrRP (19 P 2-L 31) from organs, first, 10 times the amount of distilled water was added to each organ, and the protease was inactivated by heating in boiling water for 10 minutes. Later, it was cooled in ice. Add glacial acetic acid (final concentration 1N), pump suctin (final concentration 1 g Zm 1) and phosphoramidone (final concentration 100 gZm 1), and homogenize with a polytron homogenizer (KI NEMAT ICA) for 1 minute. After centrifugation, the mixture was centrifuged at 17,000 xg for 30 minutes.
- KI NEMAT ICA polytron homogenizer
- the obtained organ extract was concentrated with Sep-Pak Plus C18 force 265 mg (manufactured by Waters), followed by Nature, Vol. 393, pp. 272-276 (1998) and W 97/24436.
- Pr RP (19P2-L31) described in (1) was quantified by the sandwich-EIA system of a previously reported (Japanese Patent Application No. 10-140293, WO 99/60112).
- the organ extract was concentrated by first extracting 4% acetic acid containing 86% ethanol 4m, methanol 4ml, distilled water 4m, and 4% acetic acid 4m1 sequentially to activate Sep-Pak Plus C18 cartridges.
- the localization coordinates were AP: +7.1 mm, L: 0.0 mm, and H: +2.0 mm from the in-aural line.
- the guide force was fixed to the skull with flash glue, dental cement and anchor screws.
- the guide cannula was equipped with a stainless steel dummy force cannula, AD-12 (0.35 mm OD, Acom), and was fixed with Kyabunite (Acom). After surgery, rats were housed in individual cages.
- the rats subjected to the above operation were anesthetized by intraperitoneal administration of 5 OmgZkg of pentobarbital.
- the patient was fixed in a dorsal position on a dissecting pad, exposing the left venous vein. Cut a polyethylene tube SP 35 (0.5 mm inner diameter, 0.9 mm outer diameter, Natsume Seisakusho) into a length of about 30 cm, fill it with saline containing 200 units / ml of heparin, and place it in a venous vein. .5 cm was inserted and fixed. The other end of the tube was exposed from the anterior part (dorsal side) through the dorsal subcutaneous area.
- the length of the microinjection tube was adjusted so that its tip lmm was exposed from the guide cannula.
- One end of a Teflon tube was connected to a microsyringe pump to dissolve 10 nmo 1 of phosphate buffered saline containing 0.5% ⁇ serum albumin (BSA) or Pr RP (19 P 2 -L 31) 0
- a total of 10/1 phosphate-buffered saline containing 5% BSA was injected into the third ventricle at a flow rate of 5 PL 1 Z. After 15 minutes from the end of the injection, the microinjection force neura was removed, and the Dami Ichiriki neura was fixed again with Cap Knight.
- the ligand polypeptide of the present invention has a regulatory action of oxytocin secretion (an action of promoting and suppressing oxytocin secretion). That is, since the ligand polypeptide of the present invention has a stimulating effect on oxytocin secretion, it can be used as a preventive and therapeutic drug for various diseases related to oxytocin secretion deficiency. On the other hand, since the ligand polypeptide of the present invention has a strong affinity for its receptor protein, when the dose is increased, desensitization to oxytocin secretion occurs, resulting in suppression of oxytocin secretion. It also has the effect of doing.
- the ligand polypeptide of the present invention may be used as an oxytocin secretion promoter as a weak labor, laxative hemorrhage, placental delivery, uterine remodeling failure, cesarean section, artificial abortion, milk stasis, labor induction, lactation insufficiency. , Infertility, dysmenorrhea, miscarriage, post-traumatic stress syndrome, etc., preferably weak labor, lax hemorrhage, placental delivery, uterine remodeling failure, cesarean section, abortion, milk stasis, etc. It is useful as an agent for ameliorating, preventing and treating various diseases related to oxytocin secretion such as labor, lax hemorrhage, placental delivery, and uterine remodeling failure.
- the ligand polypeptide of the present invention may be used as an oxytocin secretion inhibitor as an agent for overactive labor, tonic uterine contraction, fetal asphyxia, uterine rupture, anaplastic laceration, premature birth, Prader-Willi syndrome, dysmenorrhea, etc.
- an agent for ameliorating, preventing and treating various diseases related to secretion of oxytocin such as overwork labor, ankylosing contractions, fetal asphyxia, uterine rupture, ruptured tubules, preterm birth, and the Prader-Wi11i syndrome group.
- diseases related to secretion of oxytocin such as overwork labor, ankylosing contractions, fetal asphyxia, uterine rupture, ruptured tubules, preterm birth, and the Prader-Wi11i syndrome group.
- the ligand polypeptide of the present invention can be used as a test drug for examining oxytocin secretion function, or as an animal drug such as a milk secretion enhancer for livestock mammals such as cattle, goats and pigs. It is useful, and is also expected to be applied to production of useful substances by producing useful substances in the livestock mammals and secreting them into milk.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/868,885 US7045497B1 (en) | 1998-12-25 | 1999-12-22 | Use of peptide |
AU17981/00A AU1798100A (en) | 1998-12-25 | 1999-12-22 | Use of peptide |
EP99961301A EP1142580A1 (en) | 1998-12-25 | 1999-12-22 | Use of peptide |
CA002355254A CA2355254A1 (en) | 1998-12-25 | 1999-12-22 | Use of peptide |
KR1020017008011A KR20010082769A (ko) | 1998-12-25 | 1999-12-22 | 펩티드의 용도 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10/369585 | 1998-12-25 | ||
JP10369585A JP2000191696A (ja) | 1998-12-25 | 1998-12-25 | ペプチドの用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000038704A1 true WO2000038704A1 (fr) | 2000-07-06 |
Family
ID=18494810
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1999/007199 WO2000038704A1 (fr) | 1998-12-25 | 1999-12-22 | Utilisation d'un peptide |
Country Status (8)
Country | Link |
---|---|
US (1) | US7045497B1 (ja) |
EP (1) | EP1142580A1 (ja) |
JP (1) | JP2000191696A (ja) |
KR (1) | KR20010082769A (ja) |
CN (1) | CN1334741A (ja) |
AU (1) | AU1798100A (ja) |
CA (1) | CA2355254A1 (ja) |
WO (1) | WO2000038704A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001009182A1 (en) * | 1999-08-03 | 2001-02-08 | Oy Juvantia Pharma Ltd. | Prolactin-releasing peptide and method for regulating autonomic functions and treating pain |
US6884596B2 (en) | 2000-04-28 | 2005-04-26 | The Regents Of The University Of California | Screening and therapeutic methods for promoting wakefulness and sleep |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1230928A4 (en) * | 1999-11-18 | 2004-01-28 | Takeda Chemical Industries Ltd | USE OF PEPTIDE |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998058962A1 (en) * | 1997-06-23 | 1998-12-30 | Takeda Chemical Industries, Ltd. | Prolactin secretion modulator |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0870020B1 (en) * | 1995-12-28 | 2006-08-09 | Takeda Pharmaceutical Company Limited | Ligand polypeptides for the pituitary g-protein-coupled receptor protein, their production and use |
-
1998
- 1998-12-25 JP JP10369585A patent/JP2000191696A/ja not_active Withdrawn
-
1999
- 1999-12-22 AU AU17981/00A patent/AU1798100A/en not_active Abandoned
- 1999-12-22 CN CN99816067A patent/CN1334741A/zh active Pending
- 1999-12-22 EP EP99961301A patent/EP1142580A1/en not_active Withdrawn
- 1999-12-22 CA CA002355254A patent/CA2355254A1/en not_active Abandoned
- 1999-12-22 US US09/868,885 patent/US7045497B1/en not_active Expired - Fee Related
- 1999-12-22 KR KR1020017008011A patent/KR20010082769A/ko not_active Application Discontinuation
- 1999-12-22 WO PCT/JP1999/007199 patent/WO2000038704A1/ja not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998058962A1 (en) * | 1997-06-23 | 1998-12-30 | Takeda Chemical Industries, Ltd. | Prolactin secretion modulator |
Non-Patent Citations (4)
Title |
---|
BOERSMA ET AL.: "Immunocytochemical localization of neuropeptide FF(FMRF amide-like peptide) in the hypothalamo-neurohypophyseal system of wistar and brattleboro rats by light and electron microscopy", THE JOURNAL OF COMPARATIVE NEUROLOGY,, vol. 336, 1993, pages 555 - 570, XP002926479 * |
HINUMA ET AL.: "A prolactin-releasing peptide in the brain", NATURE,, vol. 393, 21 May 1998 (1998-05-21), pages 272 - 276, XP002926478 * |
MARUYAMA ET AL.: "Central administration of prolactin-releasing peptide stimulates oxitocin release in rats", NEUROSCIENCE LETTERS,, vol. 276, 1999, pages 193 - 196, XP002926476 * |
MARUYAMA ET AL.: "Immunocytochemical localization of prolactin-releasing peptide in the rat brain", ENDOCRINOLOGY,, vol. 140, no. 5, 1999, pages 2326 - 2333, XP002926477 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001009182A1 (en) * | 1999-08-03 | 2001-02-08 | Oy Juvantia Pharma Ltd. | Prolactin-releasing peptide and method for regulating autonomic functions and treating pain |
US6884596B2 (en) | 2000-04-28 | 2005-04-26 | The Regents Of The University Of California | Screening and therapeutic methods for promoting wakefulness and sleep |
Also Published As
Publication number | Publication date |
---|---|
US7045497B1 (en) | 2006-05-16 |
CA2355254A1 (en) | 2000-07-06 |
KR20010082769A (ko) | 2001-08-30 |
CN1334741A (zh) | 2002-02-06 |
EP1142580A1 (en) | 2001-10-10 |
AU1798100A (en) | 2000-07-31 |
JP2000191696A (ja) | 2000-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20010033601A (ko) | 폴리펩티드, 그의 제법 및 용도 | |
WO2000024890A1 (fr) | Nouvellesroteines receptrices couplees aux proteines g, leurs adn et leursigands | |
KR20010085847A (ko) | 펩티드 유도체 | |
WO2006041205A1 (ja) | 血管形成促進剤 | |
KR20020008111A (ko) | 스크리닝 방법 | |
US7309693B2 (en) | Preventives and remedies for pulmonary hypertension | |
EP1967210A1 (en) | Novel application of apelin | |
WO2000071151A1 (fr) | Regulateurs des fonctions hepatiques | |
CA2090703A1 (en) | Insulin-like growth factor binding protein (igfbp-4) | |
WO2000038704A1 (fr) | Utilisation d'un peptide | |
WO2001066134A1 (fr) | Agent de regulation de la secretion de prolactine contenant du rfrp | |
WO2002003070A1 (fr) | Procede de criblage d'antagoniste/agoniste du recepteur de l'hormone de concentration de la melanine (mch) | |
WO2000008053A1 (fr) | Proteine recepteur couplee a une nouvelle proteine g et son adn | |
EP1241257A1 (en) | Novel tachykinin-like polypeptides and use thereof | |
JP4306816B2 (ja) | 新規生理活性物質、その製造法および用途 | |
WO2001035984A1 (fr) | Utilisation de peptide | |
JP2002173444A (ja) | ペプチドの用途 | |
JP2002233369A (ja) | 新規タンパク質およびそのdna | |
JP2002233386A (ja) | Rfrp含有プロラクチン分泌調節剤 | |
JP2002047203A (ja) | 肺高血圧症予防・治療剤 | |
JP2002233376A (ja) | 新規タンパク質およびそのdna | |
JP2002233368A (ja) | 新規タンパク質およびそのdna | |
JP2003000266A (ja) | 新規タンパク質およびそのdna | |
JP2000159795A (ja) | ペプチド誘導体 | |
JP2002296277A (ja) | Mch受容体アンタゴニスト・アゴニストのスクリーニング方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99816067.9 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2000 17981 Country of ref document: AU Kind code of ref document: A |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AU AZ BA BB BG BR BY CA CN CR CU CZ DM EE GD GE HR HU ID IL IN IS KG KR KZ LC LK LR LT LV MA MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT TZ UA US UZ VN YU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1999961301 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2355254 Country of ref document: CA Ref document number: 2355254 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09868885 Country of ref document: US Ref document number: 1020017008011 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017008011 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1999961301 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1020017008011 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999961301 Country of ref document: EP |